These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 20515495)

  • 61. Deregulated signalling networks in human brain tumours.
    Grzmil M; Hemmings BA
    Biochim Biophys Acta; 2010 Mar; 1804(3):476-83. PubMed ID: 19879382
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma.
    Areeb Z; Stuart SF; West AJ; Gomez J; Nguyen HPT; Paradiso L; Zulkifli A; Jones J; Kaye AH; Morokoff AP; Luwor RB
    Sci Rep; 2020 Oct; 10(1):17768. PubMed ID: 33082482
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Verbascoside inhibits progression of glioblastoma cells by promoting Let-7g-5p and down-regulating HMGA2 via Wnt/beta-catenin signalling blockade.
    Jia WQ; Zhu JW; Yang CY; Ma J; Pu TY; Han GQ; Zou MM; Xu RX
    J Cell Mol Med; 2020 Mar; 24(5):2901-2916. PubMed ID: 32000296
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma.
    Jhaveri A; Deshpande P; Pattni B; Torchilin V
    J Control Release; 2018 May; 277():89-101. PubMed ID: 29522834
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
    Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
    Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells.
    Liu S; Tang Y; Yuan X; Yuan D; Liu J; Li B; Li Y
    Invest New Drugs; 2018 Dec; 36(6):961-969. PubMed ID: 29508248
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma.
    Shang C; Tang W; Pan C; Hu X; Hong Y
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):671-678. PubMed ID: 29397407
    [TBL] [Abstract][Full Text] [Related]  

  • 68. miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.
    Li S; Zeng A; Hu Q; Yan W; Liu Y; You Y
    Neuro Oncol; 2017 Jan; 19(1):55-65. PubMed ID: 27471108
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Chemo-resistance of A172 glioblastoma cells is controlled by miR-1271-regulated Bcl-2.
    Yang L; Wang Y; Li YJ; Zeng CC
    Biomed Pharmacother; 2018 Dec; 108():734-740. PubMed ID: 30248541
    [TBL] [Abstract][Full Text] [Related]  

  • 70. P144, a Transforming Growth Factor beta inhibitor peptide, generates antitumoral effects and modifies SMAD7 and SKI levels in human glioblastoma cell lines.
    Gallo-Oller G; Vollmann-Zwerenz A; Meléndez B; Rey JA; Hau P; Dotor J; Castresana JS
    Cancer Lett; 2016 Oct; 381(1):67-75. PubMed ID: 27473823
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Characterization of molecular pathways for targeting therapy in glioblastoma.
    Wagle N; Nguyen M; Carrillo J; Truong J; Dobrawa L; Kesari S
    Chin Clin Oncol; 2020 Dec; 9(6):77. PubMed ID: 33353366
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Control of oncogenesis and cancer therapy resistance.
    Perona R; Sánchez-Pérez I
    Br J Cancer; 2004 Feb; 90(3):573-7. PubMed ID: 14760366
    [TBL] [Abstract][Full Text] [Related]  

  • 73. From signalling pathways to targeted therapies: unravelling glioblastoma's secrets and harnessing two decades of progress.
    Dewdney B; Jenkins MR; Best SA; Freytag S; Prasad K; Holst J; Endersby R; Johns TG
    Signal Transduct Target Ther; 2023 Oct; 8(1):400. PubMed ID: 37857607
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Glioblastomas: Hijacking Metabolism to Build a Flexible Shield for Therapy Resistance.
    Bailleul J; Vlashi E
    Antioxid Redox Signal; 2023 Nov; 39(13-15):957-979. PubMed ID: 37022791
    [No Abstract]   [Full Text] [Related]  

  • 75. Targeting apoptosis in cancer therapy.
    Carneiro BA; El-Deiry WS
    Nat Rev Clin Oncol; 2020 Jul; 17(7):395-417. PubMed ID: 32203277
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Molecularly Targeted Clinical Trials.
    Smith-Cohn MA; Celiku O; Gilbert MR
    Neurosurg Clin N Am; 2021 Apr; 32(2):191-210. PubMed ID: 33781502
    [TBL] [Abstract][Full Text] [Related]  

  • 77. TLR-4/Wnt modulation as new therapeutic strategy in the treatment of glioblastomas.
    Casili G; Caffo M; Campolo M; Barresi V; Caruso G; Cardali SM; Lanza M; Mallamace R; Filippone A; Conti A; Germanò A; Cuzzocrea S; Esposito E
    Oncotarget; 2018 Dec; 9(101):37564-37580. PubMed ID: 30680070
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Anoctamins and Calcium Signalling: An Obstacle to EGFR Targeted Therapy in Glioblastoma?
    Dewdney B; Ursich L; Fletcher EV; Johns TG
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497413
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hallmarks of cancer: the next generation.
    Hanahan D; Weinberg RA
    Cell; 2011 Mar; 144(5):646-74. PubMed ID: 21376230
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Glioma biology and molecular markers.
    Cohen AL; Colman H
    Cancer Treat Res; 2015; 163():15-30. PubMed ID: 25468223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.